# JOHNSON & JOHNSON

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 200406. Source: https://holderbook.com/funds/200406-johnson-johnson/

- Reported value: $798.7M
- Positions: 15
- Weight of the ten largest: 98.4%
- Filed: 2026-08-06

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| PROTAGONIST THERAPEUTICS INC | [PTGX](https://holderbook.com/stocks/PTGX/) | $300.2M | 2,449,183 | 37.6% | 20 |
| NANOBIOTIX | [NBTX](https://holderbook.com/stocks/NBTX/) | $212.0M | 5,623,816 | 26.5% | 12 |
| MEIRAGTX HLDGS PLC | [MGTX](https://holderbook.com/stocks/MGTX/) | $89.7M | 6,641,064 | 11.2% | 20 |
| RAPPORT THERAPEUTICS INC | [RAPP](https://holderbook.com/stocks/RAPP/) | $74.4M | 1,784,517 | 9.3% | 9 |
| CONTINEUM THERAPEUTICS INC | [CTNM](https://holderbook.com/stocks/CTNM/) | $32.4M | 1,979,173 | 4.1% | 9 |
| LEGEND BIOTECH CORP | [LEGN](https://holderbook.com/stocks/LEGN/) | $23.5M | 814,586 | 2.9% | 20 |
| CVRX INC | [CVRX](https://holderbook.com/stocks/CVRX/) | $20.7M | 4,024,861 | 2.6% | 20 |
| XENCOR INC | [XNCR](https://holderbook.com/stocks/XNCR/) | $12.0M | 748,062 | 1.5% | 19 |
| CEREBRAS SYSTEMS INC | [CBRS](https://holderbook.com/stocks/CBRS/) | $11.8M | 53,586 | 1.5% | 1 |
| FATE THERAPEUTICS INC | [FATE](https://holderbook.com/stocks/FATE/) | $9.1M | 3,379,064 | 1.1% | 20 |
| PROCEPT BIOROBOTICS CORP | [PRCT](https://holderbook.com/stocks/PRCT/) | $8.1M | 357,939 | 1.0% | 20 |
| NEUMORA THERAPEUTICS INC. | [NMRA](https://holderbook.com/stocks/NMRA/) | $3.1M | 1,849,445 | 0.4% | 12 |
| VOR BIOPHARMA INC | [VOR](https://holderbook.com/stocks/VOR/) | $989.2K | 53,732 | 0.1% | 3 |
| STANDARD BIOTOOLS INC | [LAB](https://holderbook.com/stocks/LAB/) | $256.7K | 311,967 | 0.0% | 10 |
| ADICET BIO INC | [ACET](https://holderbook.com/stocks/ACET/) | $196.8K | 22,779 | 0.0% | 3 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +21.0% | +14.8% | +6.2% | 100% |
| Q1 2026 | +18.0% | -4.6% | +22.7% | 100% |
| Q4 2025 | +14.0% | +2.4% | +11.7% | 99% |
| Q3 2025 | +56.7% | +7.8% | +48.9% | 100% |
| Q2 2025 | -0.0% | +10.5% | -10.5% | 100% |
| Q1 2025 | -11.5% | -4.6% | -6.9% | 100% |
| Q4 2024 | -9.7% | +2.1% | -11.9% | 100% |
| Q3 2024 | +7.2% | +5.4% | +1.7% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $798.7M | 15 |
| Q1 2026 | $652.4M | 16 |
| Q4 2025 | $555.0M | 17 |
| Q3 2025 | $503.9M | 20 |
| Q2 2025 | $334.1M | 20 |
| Q1 2025 | $341.9M | 20 |
| Q4 2024 | $386.1M | 20 |
| Q3 2024 | $427.3M | 20 |
| Q2 2024 | $400.7M | 20 |
| Q1 2024 | $4.4B | 22 |
| Q4 2023 | $4.4B | 23 |
| Q3 2023 | $271.5M | 24 |